Sugi Predict

Sugi Predict / Compounds / SCHEMBL2479099

SCHEMBL2479099

SCHEMBL2479099

O=C(O)c1cccc(C(F)(F)F)c1Br

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS2R14 Q9NYV8 6/20 0.67
▸ LMNA P02545 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ FABP4 P15090 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MYC P01106 1/20 0.44
▸ DHODH Q02127 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ NR4A1 P22736 1/20 0.42
▸ NR4A2 P43354 1/20 0.42
▸ NR4A3 Q92570 1/20 0.42
▸ KCNK3 O14649 1/20 0.42
▸ KCNK9 Q9NPC2 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALB P02768 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27978211 0.83 TAS2R14 (0.53) TAS2R14LMNAGAAALDH1A1SMN1; SMN2
SCHEMBL27925017 0.83 TAS2R14 (0.53) TAS2R14LMNAGAAFABP4ALDH1A1
SCHEMBL31693161 0.83 TAS2R14 (0.53) TAS2R14LMNAGAAFABP4SMN1; SMN2
SCHEMBL2473776 0.83 TAS2R14 (0.53) TAS2R14LMNAGAAFABP4SMN1; SMN2
SCHEMBL28837084 0.82 TAS2R14 (0.51) TAS2R14LMNAGAAALDH1A1MYC
SCHEMBL21810462 0.81 TAS2R14 (0.46) TAS2R14FABP4ALDH1A1KMT2ASMN1; SMN2
SCHEMBL221518 0.79 LMNA (0.62) TAS2R14LMNAGAAFABP4ALDH1A1
SCHEMBL30449216 0.79 LMNA (0.62) TAS2R14LMNAGAAFABP4ALDH1A1
SCHEMBL30689795 0.79 TAS2R14 (0.52) TAS2R14LMNAGAAALDH1A1SMN1; SMN2
SCHEMBL22403860 0.79 TAS2R14 (0.52) TAS2R14LMNAGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024255762-A1 CBL-B INHIBITOR 上海齐鲁制药研究中心有限公司 2024-12-19 — — WO disclosed
CN-110505874-A Molecule and relative intermediate, composition and method with desinsection effectiveness DOW AGROSCIENCES LLC 2019-11-26 — — CN disclosed
EP-2697213-B1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES HIVIH (FR) 2018-12-12 — — EP disclosed
EP-3212642-A1 AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyT Janssen Pharmaceutica NV (BE) 2017-09-06 — — EP disclosed
CN-107001286-A The assimilation compound of dihydro-pyrimidin 2 and its medical usage 日本烟草产业株式会社 2017-08-01 — — CN disclosed
US-9604900-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-03-28 — — US disclosed
US-9604900-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-03-28 — — US disclosed
WO-2016069978-A1 AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT JANSSEN PHARMACEUTICA NV (BE) 2016-05-06 — — WO disclosed
EP-2374794-B1 CYCLIC AMINE COMPOUNDS DAIICHI SANKYO CO LTD (JP) 2015-11-04 — — EP disclosed
CN-104379560-A Benzamide derivative CHUGAI PHARMACEUTICAL CO LTD 2015-02-25 — — CN disclosed
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2010-05-06 — — US disclosed
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2010-05-06 — — US disclosed
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2010-05-06 — — US disclosed
CN-101679346-A substituted benzoylamino-indan-2-carboxylic acids and related compounds SANOFI AVENTIS 2010-03-24 — — CN disclosed
EP-2155711-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS Sanofi-Aventis (FR) 2010-02-24 — — EP disclosed
US-7652013-B2 Inhibitors of stearoyl-CoA desaturase HOFFMAN-LA ROCHE INC. (US) 2010-01-26 — — US disclosed
WO-2009074487-A1 INHIBITORS OF STEAROYL-COA DESATURASE F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 — — WO disclosed
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE GILLESPIE PAUL 2009-06-11 — — US disclosed
WO-2008151211-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2008-12-11 — — WO disclosed
WO-2008151211-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2008-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE SCD, SCD5, FADS2 TAS2R14 3058/4885LMNA 2327/4885GAA 279/4885
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS CXCR5, CXCR1, CCR5 TAS2R14 1115/4885LMNA 4505/4885GAA 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.